mRNA, widely known from the COVID-19 vaccine, is not actually a “therapeutic agent,” but a technology that delivers the blueprint for functional proteins in the body and induces therapeutic effects. Recently, its application has expanded to cancer and genetic disease treatments, but mRNA therapeutics have caused serious side effects such as pulmonary embolism, stroke, thrombosis, and autoimmune diseases because proteins are excessively produced all at once immediately after administration. Technology to control the endogenous protein factory is needed, but there has been no suitable solution.
Adjustable DNA ‘shield’ can control timing and rate at which mRNA produces proteins in vivo
